Tools   Select Another Resource Report Type

http://www.mtf.org

The Musculoskeletal Transplant Foundation is a non-profit service organization dedicated to providing quality allograft tissue through a commitment to excellence in education, research, recovery and care for recipients, donors and their families. We are a national consortium comprised of academic medical institutions, organ procurement organizations and tissue recovery organizations. MTF was created as a charitable organization with a mission that is dedicated to the needs of donors, donor families, patients and surgeons. We focus on respectful stewardship of the donated gift while advancing the science and practice of bone, ligament, cartilage and skin transplantation. Since our inception in 1987, MTF has recovered more than 60,000 donors and distributed more than 3 million grafts for transplantation. We also support research to expand the science of transplantation, and we encourage the efforts of our members and non-member clients to improve the understanding of donation and transplantation among the medical community and the public at large. Our policies are developed and implemented by MTF''''s Medical Board of Trustees, Donation Board of Trustees and Board of Directors, composed of physicians and recovery agency representatives who are dedicated to the mission of the Foundation. This fundamental commitment enables us to set and maintain the highest levels of safety assurance and quality control in all phases of our operations.

Proper citation: Musculoskeletal Transplant Foundation - MTF (RRID:SCR_006684) Copy   

•   Source: SciCrunch Registry

http://molonc.bccrc.ca/platforms/btb/

The Molecular Oncology department hosts the breast cancer tumour tissue repository (BREAST-TTR), a project within the agency-wide tumour tissue repository. The BREAST-TTR comprises several important banks of breast tissues, contemporaneous as well as archival. The main banks are: * 3000 frozen breast cancers, linked to 15 year outcomes data from the BCCA Breast Cancer Outcomes Unit. This archival bank consists of frozen tissue, DNA and RNA, and a tissue microarray of the cases. * Live-cryopreserved cancers. At present around 50 individual cases of metastatic breast cancer, with tumour material cryopreserved for subsequent cell culture/xenograft work. * Comptemporary bank. Between the TTR in Victoria and the accrual site in Vancouver, approximately 1300 contemporaneous (within last 4 years) breast cancers with matched normal DNA and outcomes linkages.

Proper citation: British Columbia Breast Cancer Tumour Bank (RRID:SCR_006671) Copy   

•   Source: SciCrunch Registry

http://digestive.niddk.nih.gov/statistics/statistics.aspx

A collection of statistics about specific digestive diseases, including prevalence, mortality, care delivery and cost.

Proper citation: Digestive Diseases Statistics for the United States (RRID:SCR_006703) Copy   

•   Source: SciCrunch Registry

http://ncrad.iu.edu/

Cell repository for Alzheimer's disease that collects and maintains biological specimens and associated data. Its data is derived from large numbers of genetically informative, phenotypically well-characterized families with multiple individuals affected with Alzheimer's disease, as well as individuals for case-control studies.

Proper citation: National Cell Repository for Alzheimer's Disease (RRID:SCR_007313) Copy   

•   Source: SciCrunch Registry

http://www.oasis-brains.org/

Project aimed at making neuroimaging data sets of brain freely available to scientific community. By compiling and freely distributing neuroimaging data sets, future discoveries in basic and clinical neuroscience are facilitated.

Proper citation: Open Access Series of Imaging Studies (RRID:SCR_007385) Copy   

•   Source: SciCrunch Registry

http://bioinformatics.istge.it/cldb/indexes.html

Hypertext on cell culture availability extracted from the Cell Line Data Base of the Interlab Project. HyperCLDB includes links to records of OMIM, the Online Mendelian Inheritance in Man Catalogue, and now also links to the PubMed, database of bibliographic biomedical references, which are drawn primarily from MEDLINE and PREMEDLINE.

Proper citation: Hyper Cell Line Database (RRID:SCR_007730) Copy   

•   Source: SciCrunch Registry

http://mirgator.kobic.re.kr/

Database of compiled, public, deep sequencing miRNA data and several novel tools to facilitate exploration of massive data. The miR-seq browser supports users to examine short read alignment with the secondary structure and read count information available in concurrent windows. Features such as sequence editing, sorting, ordering, import and export of user data are of great utility for studying iso-miRs, miRNA editing and modifications. miRNA����??target relation is essential for understanding miRNA function. Coexpression analysis of miRNA and target mRNAs, based on miRNA-seq and RNA-seq data from the same sample, is visualized in the heat-map and network views where users can investigate the inverse correlation of gene expression and target relations, compiled from various databases of predicted and validated targets.

Proper citation: miRGator (RRID:SCR_007793) Copy   

•   Source: SciCrunch Registry

http://www.ebi.ac.uk/ipd/hpa/

A centralised repository for the data which define the human platelet antigens (HPA). Alloantibodies against human platelet antigens are involved in neonatal alloimmune thrombocytopenia, post-transfusion purpura and refractoriness to random donor platelets. The Human Platelet Antigen (HPA) nomenclature system was adopted in 1990 to overcome problems with the previous nomenclature. Since then more antigens have been described and meanwhile the molecular basis of many has been resolved, and the nomenclature was revised in 2003.

Proper citation: IPD-HPA - Human Platelet Antigens (RRID:SCR_007747) Copy   

•   Source: SciCrunch Registry

http://bioinformatics.istge.it/cldb/mpdb.html

A database containing information on ca. 4300 synthetic oligonucleotides with a sequence of up to 100 nucleotides. Data are mainly taken from the literature and are encoded on the basis of controlled vocabularies. The probes target 821 different genes, of which 691 human and 112 viral. The probes can be used for genetic polymorphisms study (1944), human inherited disease diagnosis (834), cancer diagnosis (517), infectious disease diagnosis (517), neurologic disease diagnosis (72), autoimmune disease diagnosis (40). Oligonucleotides are described on the basis of: name, oligo type (primer, probe, antisense), nucleotide sequence, amino acid sequence (if part of a coding region), target gene and related infos (localization within the gene and recognized variants or specificities), applications, methods, technical notes, complementary primer (if used for PCR), primers for amplification (if probe), bibliographic references. At the moment MPDB is searchable through some SRS servers. MPDB can easily be retrieved from our FTP server, together with SRS syntax files. Typology * ca. 4300 oligonucleotides * 821 different genes, of which 691 human and 112 viral * ca. 3536 oligonucleotides are human gene specific * ca. 620 oligonucleotides are viral gene specific

Proper citation: MPDB - Molecular Probe Database (RRID:SCR_007808) Copy   

•   Source: SciCrunch Registry

http://www.sci.unisannio.it/docenti/rampone/

Data set of Homo Sapiens Exons, Introns and Splice regions extracted from GenBank Rel.123 with an aim of giving standardized material to train and to assess the prediction accuracy of computational approaches for gene identification and characterization. From the complete GenBank (Primate Sequences Division) Rel.123 (162,557 entries), entries of Human Nuclear DNA including Complete CDS and more than one Exon have been selected, and 4523 exons and 3802 introns have been extracted from these entries. Details about extracted exons and introns are reported (Locus, number, Start and End position in the entry, sequence, length, G+C content, presence of not AGCT data (nucleotide scan check)). Statistics are also reported (overall nucleotides, average G+C content, nucleotide scan check results, number of not GT starting / AG ending introns, minimum / maximum / average length, length standard deviation). 3799+3799 donor and acceptor sites, as windows of 140 nucleotides around each splice site have been extracted. After discarding sequences not including canonical GTAG junctions (65+74), including insufficient data (not enough material for a 140 nucleotide window) (686+589), including not AGCT bases (29+30), and redundant (218+226) there are 2796+ 2880 windows. Finally, there are 271,937 + 332,296 windows of false splice sites, selected by searching canonical GTAG pairs in not splicing positions. The false sites in a range of +/- 60 from a true splice site are marked as proximal.

Proper citation: HS3D - Homo Sapiens Splice Sites Dataset (RRID:SCR_002939) Copy   

•   Source: SciCrunch Registry

http://fcon_1000.projects.nitrc.org/indi/pro/BeijingShortTR.html

Dataset of resting state fMRI scans obtained using two different TR's in healthy college-aged volunteers. Specifically, for each participant, data is being obtained with a short TR (0.4 seconds) and a long TR (2.0 seconds). In addition this dataset contains a 64-direction DTI scan for every participant. The following data are released for every participant: * 8-minute resting-state fMRI scan (TR = 2 seconds, # repetitions = 240) * 8-minute resting-state fMRI scans (TR = 0.4 seconds, # repetitions = 1200) * MPRAGE anatomical scan, defaced to protect patient confidentiality * 64-direction diffusion tensor imaging scan (2mm isotropic) * Demographic information

Proper citation: Beijing: Short TR Study (RRID:SCR_003502) Copy   

•   Source: SciCrunch Registry

http://fcon_1000.projects.nitrc.org/indi/abide/

Resting state functional magnetic resonance imaging (R-fMRI) datasets from 539 individuals with autism spectrum disorder (ASD) and 573 typical controls. This initiative involved 16 international sites, sharing 20 samples yielding 1112 datasets composed of both MRI data and an extensive array of phenotypic information common across nearly all sites. This effort is expected to facilitate discovery science and comparisons across samples. All datasets are anonymous, with no protected health information included.

Proper citation: ABIDE (RRID:SCR_003612) Copy   

•   Source: SciCrunch Registry

http://ranchobiosciences.com/gse13168/

Curated data set from a study that assessed the effects of epidermal growth factor and interleukin 1-beta stimulation, and the modulatory effects of glucocorticoids treatment and protein kinase A inhibition, on the airway smooth muscle transcriptome by microarray analysis. The samples from 4 donors were subjected to different stimulations by Il-1b and EGF (or both) with or without pre-treatment with fluticasone, and data was collected at different timepoints.

Proper citation: GSE13168 (RRID:SCR_003651) Copy   

•   Source: SciCrunch Registry

http://qnl.bu.edu/SLDB

Curated lists of genes associated to speech / language phenotypes and structural or functional abnormalities observed in patient populations. Entrez ID gene information, as well as gene expression profiles from the Allen Brain Atlas are available. You can also download expression data for a given gene in JSON or XML format.

Proper citation: Speech Language Disorders Database (RRID:SCR_003655) Copy   

•   Source: SciCrunch Registry

http://ranchobiosciences.com/gse8650/

Curated data set from analyzed gene expression profiles in 19 pediatric patients with SoJIA during the systemic phase of the disease (fever and/or arthritis), 25 SoJIA patients with no systemic symptoms (arthritis only or no symptoms), 39 healthy controls, 94 pediatric patients with acute viral and bacterial infections (available under GSE6269), 38 pediatric patients with Systemic Lupus Erythematosus (SLE), and 6 patients with a second IL-1 mediated disease known as PAPA syndrome.

Proper citation: GSE8650 (RRID:SCR_003647) Copy   

•   Source: SciCrunch Registry

http://www.icpsr.umich.edu/icpsrweb/ICPSR/studies/03253

Data set from six research sites that examined the feasibility and outcomes of the most promising home and community-based intervention approaches for enhancing family caregiving for Alzheimers Disease (AD) and related disorders (ADRD). A unique feature is the examination of AD burdens and interventions in three ethnic groups (Caucasians, Hispanics, and African Americans). Caregiver/care recipient dyads are entered into the study using standardized eligibility criteria. The dyads are randomized at each intervention site using site-specific procedures. Standardized assessment batteries are administered at baseline, 6, 12, and 18 months. The five general types of REACH interventions are: Individual Information and Support strategies that increase caregivers' understanding of dementia and their particular caregiving situation; Group Support and Family Systems efforts that provide caregivers with multiple forms of social support; Psychoeducational and Skill-Based Training approaches that teach caregivers coping and behavioral management strategies; Home-Based Environmental interventions that modify the home environment's effect on the care recipient and support the caregiver; and Enhanced Technology Systems such as home-centered computer/telephone networks that are designed to reduce caregiver distress and isolation. REACH II was funded in 2001 to test a single multi-component intervention among family caregivers of persons with ADRD, building upon the findings of REACH. Recruitment for REACH II was completed in January 2004 with 642 participants entering the study across 5 participating sites.

Proper citation: Resources for Enhancing Alzheimers Caregiver Health (RRID:SCR_003638) Copy   

•   Source: SciCrunch Registry

https://www.ngvbcc.org/

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on January 11, 2023. Archiving services, insertional site analysis, pharmacology and toxicology resources, and reagent repository for academic investigators and others conducting gene therapy research. Databases and educational resources are open to everyone. Other services are limited to gene therapy investigators working in academic or other non-profit organizations. Stores reserve or back-up clinical grade vector and master cell banks. Maintains samples from any gene therapy related Pharmacology or Toxicology study that has been submitted to FDA by U.S. academic investigator that require storage under Good Laboratory Practices. For certain gene therapy clinical trials, FDA has required post-trial monitoring of patients, evaluating clinical samples for evidence of clonal expansion of cells. To help academic investigators comply with this FDA recommendation, the NGVB offers assistance with clonal analysis using LAM-PCR and LM-PCR technology.

Proper citation: National Gene Vector Biorepository (RRID:SCR_004760) Copy   

•   Source: SciCrunch Registry

http://www.cmrr.umn.edu/

Biomedical technology research center that focuses on development of unique magnetic resonance (MR) imaging and spectroscopy methodologies and instrumentation for the acquisition of structural, functional, and biochemical information non-invasively in humans, and utilizing this capability to investigate organ function in health and disease. The distinctive feature of this resource is the emphasis on ultrahigh magnetic fields (7 Tesla and above), which was pioneered by this BTRC. This emphasis is based on the premise that there exists significant advantages to extracting biomedical information using ultrahigh magnetic fields, provided difficulties encountered by working at high frequencies corresponding to such high field strengths can be overcome by methodological and engineering solutions. This BTRC is home to some of the most advanced MR instrumentation in the world, complemented by human resources that provide unique expertise in imaging physics, engineering, and signal processing. No single group of scientists can successfully carry out all aspects of this type of interdisciplinary biomedical research; by bringing together these multi-disciplinary capabilities in a synergistic fashion, facilitating these interdisciplinary interactions, and providing adequate and centralized support for them under a central umbrella, this BTRC amplifies the contributions of each of these groups of scientists to basic and clinical biomedical research. Collectively, the approaches and instrumentation developed in this BTRC constitute some of the most important tools used today to study system level organ function and physiology in humans for basic and translational research, and are increasingly applied world-wide. CMRR Faculty conducts research in a variety of areas including: * High field functional brain mapping in humans; methodological developments, mechanistic studies, and neuroscience applications * Metabolism, bioenergetics, and perfusion studies of human pathological states (tumors, obesity, diabetes, hepatic encephalopathy, cystic fibrosis, and psychiatric disorders) * Cardiac bioenergetics under normal and pathological conditions * Automated magnetic field shimming methods that are critical for spectroscopy and ultrafast imaging at high magnetic fields * Development of high field magnetic resonance imaging and spectroscopy techniques for anatomic, physiologic, metabolic, and functional studies in humans and animal models * Radiofrequency (RF) pulse design based on adiabatic principles * Development of magnetic resonance hardware for high fields (e.g. RF coils, pre-amplifiers, digital receivers, phased arrays, etc.) * Development of software for data analysis and display for functional brain mapping.

Proper citation: Center for Magnetic Resonance Research (RRID:SCR_003148) Copy   

•   Source: SciCrunch Registry

http://fcon_1000.projects.nitrc.org/indi/pro/Quiron-Valencia.html

Resting state datasets, including an anatomical as well as a resting state fMRI scan, collected from a community sample in Valencia, Spain. The first release includes data for 45 participants. Participants were instructed to keep their eyes open during the resting state scan, no visual stimulus was presented. The following data are released for every participant: * Scanner Type: Philips Achieva 3T-TX * One high-resolution T1-weighted mprage, defaced to protect patient confidentiality * At least one 6-minute resting state fMRI scan (R-fMRI), eyes open, no visual stimulus presented * Demographic Information

Proper citation: Quiron-Valencia Sample (RRID:SCR_003538) Copy   

•   Source: SciCrunch Registry

http://www.proteinbiotechnologies.com/

Protein Biotechnologies Inc., a San Diego, California based company, provides global pharmaceutical, biotechnology, government and academic institutions with human clinical specimen derivatives and high-throughput protein and tissue microarrays. With the largest collection of ready-to-use, clinically defined, pathology-validated human specimen derivatives on the market, Protein Biotechnologies facilitates biomedical research and drug discovery efforts for cancer, neurodegenerative diseases, cardiovascular diseases, diabetes / obesity and autoimmune disease research. To facilitate high-throughput screening of human clinical specimens, Protein Biotechnologies provides its tissue lysate library on ready-to-use protein microarrays. And, for protein localization, immunohistochemical and in-situ hybridization studies, Protein Biotechnologies'' tissue microarrays are an ideal method for studying multiple human cancer / normal tissues in a single assay. Key Products & Services: * Reverse Phase Protein Microarrays * Human Clinical Tissue Lysates * Tissue Microarrays * Primary & Secondary Antibodies * Supplemental Research Reagents * Protein, RNA and DNA Isolation and Purification * Peptide Synthesis * Custom Protein and Peptide Microarray Design and Manufacturing * Custom Antibody Production

Proper citation: Protein Biotechnologies (RRID:SCR_004893) Copy   

•   Source: SciCrunch Registry